Details of the Drug Combination

General Information of Drug Combination (ID: DCLDQ2G)

Drug Combination Name
Etonogestrel Terameprocol
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Etonogestrel   DMKA8J4 Terameprocol   DMC3P45
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 14.71
Bliss Independence Score: 14.71
Loewe Additivity Score: 20.68
LHighest Single Agent (HSA) Score: 20.69

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Etonogestrel
Disease Entry ICD 11 Status REF
Contraception QA21 Approved [2]
Etonogestrel Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Progesterone receptor (PGR) TTUV8G9 PRGR_HUMAN Binder [4]
------------------------------------------------------------------------------------
Etonogestrel Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [5]
------------------------------------------------------------------------------------
Indication(s) of Terameprocol
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 2 [3]
Terameprocol Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Transcription factor Sp1 (SP1) TTZEP6S SP1_HUMAN Modulator [3]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7590).
3 Terameprocol, a novel site-specific transcription inhibitor with anticancer activity. IDrugs. 2008 Mar;11(3):204-14.
4 Pharmacological profile of progestins. Maturitas. 2008 Sep-Oct;61(1-2):151-7.
5 The role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrel. Br J Clin Pharmacol. 2005 Jul;60(1):69-75.